Equity

12 Months Ended

Dec. 31, 2019

The following is a summary of our capital stock activity over the past three years:


	Common Stock Shares	Treasury Stock Shares
December 31, 2016	185,983,792	52,293,686
Stock options and awards	—	(640,450)

December 31, 2017	185,983,792	51,653,236
Stock options and awards	—	(390,553)
Repurchases of common stock, net	—	2,439,495
December 31, 2018	185,983,792	53,702,178
Stock options and awards	—	(1,563,307)
Repurchases of common stock, net	—	4,720,627
December 31, 2019	185,983,792	56,859,498

Accumulated other comprehensive income (loss)

Summarized below is the roll forward of accumulated other comprehensive income (loss), net of tax.


(in Millions)	Foreign currency adjustments		Derivative Instruments ⁽¹⁾		Pension and other postretirement benefits ⁽²⁾		Total
Accumulated other comprehensive income (loss), net of tax at December 31, 2016	$	(194.0)	$	7.1	$	(291.5)	$	(478.4)
2017 Activity
Other comprehensive income (loss) before reclassifications	$	173.9	$	(1.2)	$	0.6	$	173.3
Amounts reclassified from accumulated other comprehensive income (loss)	13.9		(0.7)		51.6		64.8

Accumulated other comprehensive income (loss), net of tax at December 31, 2017	$	(6.2)	$	5.2	$	(239.3)	$	(240.3)
2018 Activity
Other comprehensive income (loss) before reclassifications	$	(95.3)	$	13.7	$	4.2	$	(77.4)
Amounts reclassified from accumulated other comprehensive income (loss)	—		(7.7)		16.5		8.8

Accumulated other comprehensive income (loss), net of tax at December 31, 2018	$	(101.5)	$	11.2	$	(218.6)	$	(308.9)
2019 Activity
Other comprehensive income (loss) before reclassifications	$	(15.2)	$	(69.0)	$	(6.5)	$	(90.7)
Amounts reclassified from accumulated other comprehensive income (loss)	—		(8.2)		9.9		1.7
Net current period other comprehensive income (loss)	$	(15.2)	$	(77.2)	$	3.4	$	(89.0)
Adoption of accounting standard (Note 2)	—		1.0		(54.1)		(53.1)
Distribution of FMC Lithium ⁽³⁾	39.0		—		—		39.0

Accumulated other comprehensive income (loss), net of tax at December 31, 2019	$	(77.7)	$	(65.0)	$	(269.3)	$	(412.0)

____________________

(1)See Note 19 for more information.

(2)See Note 15 for more information.

(3)Represents the effects of the distribution of FMC Lithium. Refer to Note 1 for further information.

Reclassifications of accumulated other comprehensive income (loss)

The table below provides details about the reclassifications from accumulated other comprehensive income (loss) and the affected line items in the consolidated statements of income (loss) for each of the periods presented.


Details about Accumulated Other Comprehensive Income (Loss) Components	Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)⁽¹⁾							Affected Line Item in the Consolidated Statements of Income (Loss)
	Year Ended December 31,
(in Millions)	2019		2018		2017
Foreign currency translation adjustments:
Divestiture of FMC Health and Nutrition ⁽²⁾	$	—	$	—	$	(13.9)	Discontinued operations, net of income taxes

Derivative instruments:
Foreign currency contracts	$	10.0	$	18.9	$	(10.0)	Costs of sales and services
Energy contracts	—		—		0.8		Costs of sales and services
Foreign currency contracts	1.9		(8.0)		10.0		Selling, general and administrative expenses
Interest rate contracts	(0.7)		(0.4)		—		Interest expense
Total before tax	$	11.2	$	10.5	$	0.8
	(3.0)		(2.8)		(0.1)		Provision for income taxes
Amount included in net income	$	8.2	$	7.7	$	0.7

Pension and other postretirement benefits ⁽³⁾:
Amortization of prior service costs	$	(0.3)	$	(0.3)	$	(0.5)	Selling, general and administrative expenses
Amortization of unrecognized net actuarial and other gains (losses)	(10.8)		(14.4)		(14.4)		Selling, general and administrative expenses
Recognized loss due to settlement/curtailment	(1.4)		(6.1)		(51.2)		Selling, general and administrative expenses; Discontinued operations, net of income taxes ⁽⁴⁾
Total before tax	$	(12.5)	$	(20.8)	$	(66.1)
	2.6		4.3		14.5		Provision for income taxes
Amount included in net income	$	(9.9)	$	(16.5)	$	(51.6)

Total reclassifications for the period	$	(1.7)	$	(8.8)	$	(64.8)	Amount included in net income

____________________

(1)Amounts in parentheses indicate charges to the consolidated statements of income (loss).

(2)The reclassification of historical cumulative translation adjustments was the result of the sale of our FMC Health and Nutrition and Omega-3 business. The loss recognized from this reclassification is considered permanent for tax purposes and therefore no tax has been provided. See Note 11 within these consolidated financial statements for more information. In accordance with accounting guidance, this amount was previously factored into the lower of cost or fair value test associated with the Omega-3 asset held for sale write-down charges.

(3)Pension and other postretirement benefits amounts include the impact from both continuing and discontinued operations. For detail on the continuing operations components of pension and other postretirement benefits, see Note 15.

(4)The loss due to curtailment for the year ended December 31, 2017 related to the disposal of FMC Health and Nutrition was recorded to "Discontinued operations, net of income taxes" on the consolidated statements of income (loss).

Transactions with Noncontrolling Interest

As a result of the IPO and underwriters' exercise to purchase additional shares of common stock in the fourth quarter of 2018, our controlling interest in FMC Lithium was approximately 84 percent. On March 1, 2019, we completed the previously announced distribution of the remaining shares of common stock of Livent. See Note 1 for further information.

As part of the DuPont Crop Protection Business Acquisition, we acquired an 80 percent controlling interest in DuPont Agricultural Chemicals Limited, Shanghai, a joint venture registered in the People's Republic of China.

During the first quarter of 2017, we terminated our interest in a variable interest entity. See Note 9 for more information.

Dividends and Share Repurchases

On January 16, 2020, we paid dividends totaling $57.0 million to our shareholders of record as of December 31, 2019. This amount is included in “Accrued and other liabilities” on the consolidated balance sheets as of December 31, 2019. For the years ended December 31, 2019, 2018 and 2017, we paid $210.3 million, $89.2 million and $88.8 million in dividends, respectively.

In 2019, 4.7 million shares were repurchased under the publicly announced repurchase program. At December 31, 2019, approximately $600 million remained unused under our Board-authorized repurchase program. This repurchase program does not include a specific timetable or price targets and may be suspended or terminated at any time. Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market conditions and other factors. We also reacquire shares from time to time from employees in connection with the vesting, exercise and forfeiture of awards under our equity compensation plans.